<DOC>
	<DOCNO>NCT00004085</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance . Peripheral stem cell transplantation may able replace immune cell destroy radioimmunotherapy use kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation treat patient stage IV breast cancer .</brief_summary>
	<brief_title>Radioimmunotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity yttrium Y 90 monoclonal antibody MN-14 ( Y90 MOAB MN-14 ) plus peripheral blood stem cell rescue patient stage IV breast cancer . II . Determine pharmacokinetic profile Y90 MOAB MN-14 blood , normal organ , tumor patient population . III . Determine antibody response Y90 MOAB MN-14 patient . IV . Determine antitumor effect regimen patient . V. Determine radiation absorb dose normal organ tumor . OUTLINE : This dose-escalation , multicenter study . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) without chemotherapy day -28 -14 peripheral blood stem cell ( PBSC ) collection day -14 -11 . If adequate number CD34+ cell harvest , bone marrow may collect . Patients receive pretherapy image indium In 111 monoclonal antibody MN-14 IV 40 minute day -7 follow whole body imaging day -7 0 . Patients receive yttrium Y 90 monoclonal antibody MN-14 ( Y90 MOAB MN-14 ) IV 40 minute day 0 . PBSC bone marrow reinfused day 6 14 , depend antibody clearance . Patients receive G-CSF SC IV blood count recover . Cohorts 3-6 patient receive escalate dos Y90 MOAB MN-14 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow weekly 2 month , monthly 6 month , every 6 month 5 year . PROJECTED ACCRUAL : A total 24-30 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven stage IV breast cancer Measurable disease firstline great chemotherapy Evidence CEA expression : Serum CEA least 10 ng/mL OR Positive immunostaining primary metastatic tumor CEAspecific antibody Positive imaging least 1 confirmed tumor pretherapy indium In 111 monoclonal antibody MN14 No brain metastases Bone marrow biopsy prior stem cell mobilization require assess cellularity tumor involvement Cellularity great 60 % normal Tumor involvement le 25 % Chromosome analysis bone marrow aspirate ( optional ) No brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 70100 % OR ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 mg/dL AST le 2 time upper limit normal ( ULN ) Renal : Creatinine le 1.5 time ULN Cardiovascular : Cardiac ejection fraction great 50 % MUGA Pulmonary : DLCO great 70 % predict FVC FEV1 great 70 % predict Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No severe anorexia , nausea vomiting , urinary incontinence No significant concurrent medical problem include severe psychiatric , epileptic , diabetic disease No prisoner If receive prior chimeric humanize antibody ( e.g. , trastuzumab ( Herceptin ) ) , must allergy yttrium Y 90 monoclonal antibody MN14 PRIOR CONCURRENT THERAPY : Biologic therapy : No prior peripheral blood stem cell rescue Chemotherapy : See Disease Characteristics At least 1 course prior chemotherapy At least 4 week since prior chemotherapy No prior highdose chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy 30 % red bone marrow Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>